Hikma Bundle
What is the history of this pharmaceutical company?
Founded in 1978 by Samih Darwazah in Amman, Jordan, this multinational pharmaceutical company began with a vision to supply quality medicines to the Middle East and North Africa. Its initial focus was on making essential healthcare accessible in the MENA region.
From its origins as a local supplier, the company has experienced significant global expansion. It is now a FTSE 100 constituent, headquartered in London, with operations across North America, Europe, and the MENA region.
The company's journey from a regional entity to a global pharmaceutical leader is marked by strategic growth and a commitment to patient needs. This includes its significant presence in the US market, where it ranks as the seventh-largest supplier of generic medicines, and its strong position in the MENA region as the second-largest pharmaceutical company by sales.
In 2024, the company achieved core revenue of $3.156 billion, a 10% increase year-over-year, with core operating profit reaching $719 million. This financial performance underscores its robust market standing. The company's product portfolio includes a wide range of treatments, such as those for cardiovascular conditions and central nervous system disorders, contributing to its Hikma PESTEL Analysis.
What is the Hikma Founding Story?
The founding story of Hikma Pharmaceuticals is one of vision and determination, beginning in Amman, Jordan, in 1978. Samih Darwazah, a pharmacist with international experience, set out to create high-quality, accessible medicines for the Arab world.
The Genesis of Hikma Pharmaceuticals
Samih Darwazah, after a successful career abroad, returned to Jordan with a clear mission: to establish a pharmaceutical company that could rival Western standards. His vision was to bring advanced medical solutions to the MENA region.
- Founded in 1978 in Amman, Jordan.
- Established by Samih Darwazah, a visionary pharmacist.
- Initial focus on branded generics and in-licensed products.
- Aspired to create Arab medicine competitive with Western standards.
Darwazah's journey began with a strong educational background, including studies at the American University of Beirut and advanced medical science research in the U.S. His 12 years of experience with a multinational pharmaceutical company in Italy provided him with invaluable industry knowledge. He recognized a significant gap in the market for quality pharmaceuticals in the Arab world, which fueled his ambition to build a local enterprise. The company's initial strategy involved developing a branded pharmaceuticals business across the Middle East and North Africa (MENA) region. This involved manufacturing both branded generics and products licensed from other companies. An early strategic move was a joint venture with an Italian firm, which Darwazah soon transitioned into a fully Jordanian entity. Further solidifying its manufacturing capabilities, Hikma secured a license and a joint venture with a Japanese pharmaceutical company to produce a specific product within Jordan for the broader Middle Eastern market. The choice of the name 'Hikma,' meaning 'wisdom' in Arabic, underscored Darwazah's belief in the power of knowledge and reasoned decision-making, combined with a positive outlook, as essential for success. The initial capital for the venture was likely a combination of personal investment and support from friends in Jordan and Italy, embodying a bootstrapping approach. A defining characteristic of Hikma's early development was Darwazah's commitment to adhering to stringent US FDA standards from the very beginning. This self-imposed obligation to quality was a forward-thinking strategy, aiming to build a foundation that would eventually permit exports to the United States, a testament to the Revenue Streams & Business Model of Hikma.
Hikma SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Hikma?
The early years of the company were marked by ambitious expansion across the Middle East and North Africa, coupled with a strategic vision for global reach. From its founding in Jordan in 1978, it rapidly became a key player in branded generics and in-licensed pharmaceuticals.
Founding and MENA Establishment
Established in Jordan in 1978, the company quickly built a strong presence across the MENA region. By the 1980s, it achieved a significant milestone by operating the first US FDA-inspected manufacturing plant in the region.
Early International Steps
The company took its first steps beyond the Middle East in the 1980s by acquiring land in Portugal for a sterile injectable manufacturing plant. This facility became operational by 1990, signaling its international ambitions.
US Market Entry and FDA Approval
The 1990s saw a pivotal move into the US market with the acquisition of West-Ward Pharmaceuticals in 1991. This strategic acquisition led to the company becoming the first Arab pharmaceutical firm to secure US FDA approval in 1996.
Continued Expansion and Market Diversification
Further acquisitions in Tunisia and Saudi Arabia bolstered its MENA position, while the 2000s brought expansion into the lyophilized segment and oncology market through European acquisitions. A significant capital raise of US$124 million occurred in 2005 upon listing on the London Stock Exchange, fueling further growth and acquisitions. By 2024, the company's global workforce reached approximately 9,100 employees, a testament to its substantial growth trajectory and strategic focus on diversifying its portfolio and geographical footprint, as detailed in the Competitors Landscape of Hikma.
Hikma PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Hikma history?
The Hikma company history is marked by strategic expansion and a steadfast commitment to quality, establishing itself as a significant player in the global pharmaceutical market. From its early days, the company focused on meeting rigorous international standards, paving the way for its future achievements.
| Year | Milestone |
|---|---|
| 1995 | Established US FDA quality standards for its operations. |
| 1996 | Became the first Arab company to export pharmaceutical products to the United States. |
| 2011 | Acquired Baxter's multi-source injectables business (MSI). |
| 2024 | Acquired the US finished dosage form business of Xellia Pharmaceuticals. |
| 2024 | Secured an agreement to acquire 17 Takeda brands previously licensed to Hikma. |
| December 2024 | Launched its first GLP-1 product, liraglutide. |
| January 2025 | Signed an exclusive commercial partnership with Emergent BioSolutions for Kloxxado® naloxone nasal spray in the US. |
Innovations at Hikma Pharmaceuticals have been central to its growth, with a significant focus on expanding its product portfolio and enhancing its research and development capabilities. The company launched 89 new products across its business segments in 2024, including 12 in the US market, and introduced its first GLP-1 product, liraglutide, in December 2024. Furthermore, the establishment of a new R&D center in Zagreb, Croatia, bolsters its capacity to develop more complex pharmaceutical products.
US Market Expansion
Hikma's strategic acquisitions, such as the 2024 purchase of Xellia's US business and the 2025 partnership for Kloxxado®, have significantly strengthened its presence in the US market.
Product Portfolio Diversification
The company has tripled its generic injectables portfolio to over 160 products in the last decade and is a leading supplier of nasal sprays in the US.
R&D Advancement
The opening of a new R&D center in Zagreb, Croatia, complements existing facilities, enhancing the development of more sophisticated pharmaceutical products.
Strategic Brand Acquisitions
The 2024 agreement to acquire 17 Takeda brands previously licensed to Hikma is set to boost the profitability of its Branded segment.
GLP-1 Market Entry
The launch of liraglutide in December 2024 marks Hikma's entry into the growing GLP-1 market, demonstrating its responsiveness to emerging therapeutic areas.
Manufacturing Agility
Hikma's manufacturing sites, including the Columbus, Ohio facility, have shown adaptability in responding to market shortages, underscoring its operational resilience.
Challenges faced by Hikma Pharmaceuticals have included navigating market downturns and intense competition, particularly within the US generics sector, which led to a share price impact in 2017. The company has responded by increasing investment in research and development and expanding its contract manufacturing operations, securing new contracts expected to contribute significantly by 2027.
Market Volatility
The company has experienced periods of market downturns and faced competitive pressures, notably impacting its performance in the US generics market in 2017.
Competitive Landscape
Intense competition within the pharmaceutical industry, especially in the generics segment, requires continuous strategic adaptation and innovation to maintain market share.
Regulatory Environment
Maintaining compliance with evolving regulatory standards across different international markets, including those set by European and US authorities, presents an ongoing operational challenge.
Supply Chain Dynamics
Responding effectively to market shortages and ensuring consistent product availability requires robust supply chain management and manufacturing agility.
Integration of Acquisitions
Successfully integrating acquired businesses, such as the 2024 Xellia acquisition, demands careful planning and execution to realize synergies and operational efficiencies.
R&D Investment Balancing
Balancing significant investments in R&D for future growth with current operational demands is a continuous strategic consideration for the company.
Hikma Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Hikma?
The journey of Hikma Pharmaceuticals is a testament to strategic vision and consistent growth, beginning with its founding in Amman, Jordan, in 1978. Over the decades, the company has expanded its global reach and product offerings, marking significant milestones in its development.
| Year | Key Event |
|---|---|
| 1978 | Founded by Samih Darwazah in Amman, Jordan, marking the Brief History of Hikma. |
| 1980s | Established the first US FDA-inspected manufacturing plant in the MENA region. |
| 1991 | Acquired West-Ward Pharmaceuticals, a pivotal step in entering the US market. |
| 1996 | Became the first Arab company to export pharmaceutical products to the US, with West-Ward achieving FDA compliance. |
| 2005 | Successfully listed on the London Stock Exchange, raising US$124 million. |
| 2011 | Completed the acquisition of Baxter Healthcare Corporation's US generic injectables business. |
| 2021 | Acquired Custopharm Inc. for $425 million, significantly bolstering its US injectables segment. |
| 2024 | Acquired Xellia Pharmaceuticals' US finished dosage form business and agreed to acquire 17 Takeda brands, reporting core revenue of $3.156 billion. |
| December 2024 | Launched its first GLP-1 product, liraglutide. |
| January 2025 | Entered an exclusive commercial partnership with Emergent BioSolutions for Kloxxado® naloxone nasal spray in the US. |
| June 2025 | Announced a $1 billion investment by 2030 to expand US manufacturing and R&D capabilities. |
| July 2025 | Launched Morphine Sulfate Injection, USP, in a prefilled syringe in the US. |
Financial Performance and Outlook for 2025
Hikma Pharmaceuticals anticipates robust growth in 2025, with Group revenue projected to increase by 4% to 6%. Core operating profit is expected to range between $730 million and $770 million.
Strategic Investment in R&D and Manufacturing
The company plans a 20% increase in R&D investment across all segments to support its global pipeline. A significant $1 billion investment is earmarked by 2030 to enhance US manufacturing and R&D capabilities.
Segment-Specific Growth Projections
The Injectables segment is forecast to achieve revenue growth of 7% to 9%. Branded revenue in the MENA region is expected to grow by 6% to 7% in constant currency.
Generics Segment Focus and Market Sentiment
The Generics segment is expected to remain broadly flat, with a strategic focus on differentiated products and increased R&D investment. Analyst consensus indicates a 'Buy' rating with a forecasted upside of 28.64%.
Hikma Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of Hikma Company?
- What is Growth Strategy and Future Prospects of Hikma Company?
- How Does Hikma Company Work?
- What is Sales and Marketing Strategy of Hikma Company?
- What are Mission Vision & Core Values of Hikma Company?
- Who Owns Hikma Company?
- What is Customer Demographics and Target Market of Hikma Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.